Payment overview · 2025
General Payments
$4,073.31
135 reported records · 24 companies
Healthcare provider profile · identity verified
Yun Hee Chung, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · FLUSHING, NY · NPI 1205948668
Verified facts
What the public records show
CMS Open Payments records show Yun Hee Chung, MD received $4,073.31 in general payments during 2025 across 135 reported records.
Amgen Inc. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Linzess, Ozempic, Prolia, Shingrix, Tagrisso, Xtandi, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 752 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Tagrisso by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xtandi by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $840.29 | 20.6% | 18 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $436.01 | 10.7% | 17 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $338.65 | 8.3% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $299.57 | 7.3% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $268.49 | 6.6% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $213.11 | 5.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.40 | 4.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $180.99 | 4.4% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.16 | 3.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $141.58 | 3.5% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $131.83 | 3.2% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.19 | 3.0% | 4 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $118.53 | 2.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $112.07 | 2.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.62 | 2.1% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $76.24 | 1.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.03 | 1.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.85 | 1.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.03 | 1.7% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.08 | 1.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $26.04 | 0.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.82 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.82 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.91 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,973.36 | 134 |
| Education | $99.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $540.24 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $300.05 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $299.57 | 10 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $256.09 | 10 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $234.36 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $213.11 | 5 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $190.40 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $180.99 | 16 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $180.99 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.16 | 3 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $145.10 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $141.58 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $131.83 | 6 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $120.19 | 4 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $108.47 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $95.78 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $94.99 | 4 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $93.60 | 4 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $76.24 | 3 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $72.85 | 3 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $72.23 | 3 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $71.67 | 3 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $71.67 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $68.03 | 3 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $66.42 | 3 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $66.42 | 3 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $65.61 | 3 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $54.44 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 752 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 240 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 213 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 329 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 19 | exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
752 | 126 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
213 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
149 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
329 | 194 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
240 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1627 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 1298 | 263 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1206 | 273 |
| Diclofenac Epolamine | Diclofenac Epolamine | 898 | 167 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 872 | 194 |
| Meloxicam | Meloxicam | 837 | 222 |
| Creon | Lipase/Protease/Amylase | 752 | 126 |
| Metformin Hcl | Metformin Hcl | 748 | 163 |
| Losartan Potassium | Losartan Potassium | 578 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 551 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 514 | 108 |
| Simvastatin | Simvastatin | 477 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 443 | 93 |
| Sertraline Hcl | Sertraline Hcl | 388 | 75 |
| Januvia | Sitagliptin Phosphate | 379 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 370 | 79 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 362 | 88 |
| Dexlansoprazole Dr | Dexlansoprazole | 355 | 55 |
| Celecoxib | Celecoxib | 342 | 66 |
| Prolia | Denosumab | 329 | 194 |
| Jardiance | Empagliflozin | 315 | 54 |
| Omeprazole | Omeprazole | 313 | 75 |
| Mometasone Furoate | Mometasone Furoate | 311 | 107 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 310 | 212 |
| Donepezil Hcl | Donepezil Hcl | 296 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 60 |
| Gabapentin | Gabapentin | 283 | 63 |
| Myrbetriq | Mirabegron | 266 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 260 | 54 |
| Gemtesa | Vibegron | 240 | 60 |
| Alendronate Sodium | Alendronate Sodium | 232 | 59 |
| Trazodone Hcl | Trazodone Hcl | 229 | 46 |
| Meclizine Hcl | Meclizine Hcl | 214 | 65 |
| Linzess | Linaclotide | 213 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 195 | 52 |
| Montelukast Sodium | Montelukast Sodium | 182 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 172 | 40 |
| Metformin Hcl Er | Metformin Hcl | 170 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 155 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 31 |
| Zenpep | Lipase/Protease/Amylase | 149 | 24 |
| Atenolol | Atenolol | 147 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 137 | 70 |
| Lidocaine | Lidocaine | 137 | 23 |
| Azithromycin | Azithromycin | 136 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 24 |
| Eliquis | Apixaban | 121 | 27 |
| Finasteride | Finasteride | 112 | 28 |
| Furosemide | Furosemide | 109 | 27 |
| Lisinopril | Lisinopril | 100 | 22 |
| Letrozole | Letrozole | 98 | 25 |
| Glimepiride | Glimepiride | 97 | 20 |
| Glipizide Er | Glipizide | 97 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 18 |
| Livalo | Pitavastatin Calcium | 85 | 24 |
| Enalapril Maleate | Enalapril Maleate | 77 | 17 |
| Carvedilol | Carvedilol | 73 | 15 |
| Famotidine | Famotidine | 72 | 17 |
| Synthroid | Levothyroxine Sodium | 72 | 14 |
| Ammonium Lactate | Ammonium Lactate | 71 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | suppressed |
| Tradjenta | Linagliptin | 68 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 57 | 12 |
| Allopurinol | Allopurinol | 56 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 36 |
| Valsartan | Valsartan | 53 | 13 |
| Exemestane | Exemestane | 52 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 52 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 20 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | suppressed |
| Telmisartan | Telmisartan | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 11 |
| Restasis | Cyclosporine | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Prednisone | Prednisone | 43 | 20 |
| Tagrisso | Osimertinib Mesylate | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 38 | suppressed |
| Hydroxyurea | Hydroxyurea | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 11 |
| Folic Acid | Folic Acid | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 16 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 33 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Nexium | Esomeprazole Magnesium | 33 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | 17 |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 26 | suppressed |
| Fulvestrant | Fulvestrant | 26 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 25 | suppressed |
| Xtandi | Enzalutamide | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Dexilant | Dexlansoprazole | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Dutasteride | Dutasteride | 21 | suppressed |
| Fluocinonide | Fluocinonide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 15 |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Pomalyst | Pomalidomide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Revlimid | Lenalidomide | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,073.31 · 135 records | Amgen Inc. | AREXVY, CAPVAXIVE, CREON, Cologuard Collection Kit, Doptelet, ERLEADA, EVENITY, GARDASIL 9, GEMTESA, IBSRELA, JAKAFI, JEMPERLI, LINZESS, Lenvima, MONJUVI, NERLYNX, Nubeqa, ORGOVYX, OTEZLA, Ozempic, PEMAZYRE, PLUVICTO, PROLIA, PYRUKYND, REBLOZYL, REPATHA, Rybelsus, SCEMBLIX, SHINGRIX, Stivarga, TAGRISSO, TALZENNA, TRELEGY ELLIPTA, ULTOMIRIS, VOQUEZNA, Vemlidy, Vitrakvi, Vonjo, XTANDI, ZEJULA, ZENPEP, ZYNYZ | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error